{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:49:44Z","timestamp":1788904184939,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF15SA0018346"],"award-info":[{"award-number":["NNF15SA0018346"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF16OC0019968"],"award-info":[{"award-number":["NNF16OC0019968"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF15CC0018486"],"award-info":[{"award-number":["NNF15CC0018486"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF22SA0079901"],"award-info":[{"award-number":["NNF22SA0079901"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF22SA0079901"],"award-info":[{"award-number":["NNF22SA0079901"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF20SA0064340"],"award-info":[{"award-number":["NNF20SA0064340"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF20SA0067242"],"award-info":[{"award-number":["NNF20SA0067242"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005860","name":"Helsefonden","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["NA (study medication)"],"award-info":[{"award-number":["NA (study medication)"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Please see the manuscript for specific details and recipients of funding."},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["101212194"],"award-info":[{"award-number":["101212194"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","award":["PhD2023009-HF"],"award-info":[{"award-number":["PhD2023009-HF"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","award":["PD2-2024005-DCA"],"award-info":[{"award-number":["PD2-2024005-DCA"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Obesity and inactivity are linked to endothelial dysfunction and atherosclerosis. In this secondary analysis of the S-LiTE trial (ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04122716\" ext-link-type=\"uri\">NCT04122716<\/jats:ext-link>\n                    ; EudraCT identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2015-005585-32\" ext-link-type=\"uri\">2015\u2013005585-32<\/jats:ext-link>\n                    ), 130 adults with obesity completed a diet-induced weight loss plan, followed by randomization to weight maintenance with exercise and\/or liraglutide for 52\u2009weeks. We show that exercise, alone or in combination with liraglutide, reduces carotid intima-media thickness and systemic pro-inflammatory cytokine levels (interleukin-6 and interferon-\u03b3). Combination treatment also improves endothelial function biomarkers (sICAM-1, sVCAM-1 and tPA). Liraglutide alone shows no such improvements. Overall, regular physical activity, with or without GLP-1R agonists, is essential for promoting vascular health in adults with obesity.\n                  <\/jats:p>","DOI":"10.1038\/s42255-026-01554-4","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:02:37Z","timestamp":1782291757000},"page":"1483-1488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-6285","authenticated-orcid":false,"given":"Rasmus Michael","family":"Sandsdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haithem Ghalib Ali","family":"Alkhefagie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Rehn\u00e9","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3024-4017","authenticated-orcid":false,"given":"Christian Rimer","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-4595","authenticated-orcid":false,"given":"Sarah","family":"Byberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopameera","family":"Thirumathyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Gliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Stallknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-3805","authenticated-orcid":false,"given":"Jens Juul","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5600-5623","authenticated-orcid":false,"given":"Jens Dahlgaard","family":"Hove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bandholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1962-5302","authenticated-orcid":false,"given":"Kirstine Nyvold","family":"Bojsen-M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1815","authenticated-orcid":false,"given":"Sten","family":"Madsbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"St\u00f8rling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else Marie","family":"Bladbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Antoniades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Birk Kj\u00e6r","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6779-0252","authenticated-orcid":false,"given":"Signe S\u00f8rensen","family":"Torekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"1554_CR1","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley, T. M. et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143, e984\u2013e1010 (2021).","journal-title":"Circulation"},{"key":"1554_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/CIRCRESAHA.118.312669","volume":"124","author":"CJ Lavie","year":"2019","unstructured":"Lavie, C. J., Ozemek, C., Carbone, S., Katzmarzyk, P. T. & Blair, S. N. Sedentary behavior, exercise, and cardiovascular health. Circ. Res. 124, 799\u2013815 (2019).","journal-title":"Circ. Res."},{"key":"1554_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P Libby","year":"2002","unstructured":"Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135\u20131143 (2002).","journal-title":"Circulation"},{"key":"1554_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","volume":"7","author":"IJ Neeland","year":"2019","unstructured":"Neeland, I. J. et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 7, 715\u2013725 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1554_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.echo.2007.11.011","volume":"21","author":"JH Stein","year":"2008","unstructured":"Stein, J. H. et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J. Am. Soc. Echocardiogr. 21, 93\u2013111 (2008).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"1554_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","volume":"142","author":"P Willeit","year":"2020","unstructured":"Willeit, P. et al. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk. Circulation 142, 621\u2013642 (2020).","journal-title":"Circulation"},{"key":"1554_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","volume":"22","author":"RM Sandsdal","year":"2023","unstructured":"Sandsdal, R. M. et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc. Diabetol. 22, 41 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"1554_CR8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40279-023-01837-w","volume":"53","author":"ME Shivgulam","year":"2023","unstructured":"Shivgulam, M. E. et al. Impact of exercise training interventions on flow-mediated dilation in adults: an umbrella review. Sports Med. 53, 1161\u20131174 (2023).","journal-title":"Sports Med."},{"key":"1554_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nri3041","volume":"11","author":"M Gleeson","year":"2011","unstructured":"Gleeson, M. et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. 11, 607\u2013615 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"1554_CR10","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"New Engl. J. Med."},{"key":"1554_CR11","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR Lundgren","year":"2021","unstructured":"Lundgren, J. R. et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New Engl. J. Med. 384, 1719\u20131730 (2021).","journal-title":"New Engl. J. Med."},{"key":"1554_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1476-7120-5-29","volume":"5","author":"K Potter","year":"2007","unstructured":"Potter, K. et al. Carotid intima-medial thickness measured on multiple ultrasound frames: evaluation of a DICOM-based software system. Cardiovasc. Ultrasound 5, 29 (2007).","journal-title":"Cardiovasc. Ultrasound"},{"key":"1554_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836\u2013843 (2000).","journal-title":"N. Engl. J. Med."},{"key":"1554_CR14","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","volume":"101","author":"PM Ridker","year":"2000","unstructured":"Ridker, P. M., Rifai, N., Stampfer, M. J. & Hennekens, C. H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767\u20131772 (2000).","journal-title":"Circulation"},{"key":"1554_CR15","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1161\/01.CIR.101.18.2149","volume":"101","author":"PM Ridker","year":"2000","unstructured":"Ridker, P. M. et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101, 2149\u20132153 (2000).","journal-title":"Circulation"},{"key":"1554_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cytogfr.2008.11.003","volume":"20","author":"JE McLaren","year":"2009","unstructured":"McLaren, J. E. & Ramji, D. P. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 20, 125\u2013135 (2009).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1554_CR17","first-page":"4196","volume":"82","author":"V Mohamed-Ali","year":"1997","unstructured":"Mohamed-Ali, V. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82, 4196\u20134200 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1554_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33067-5","volume":"13","author":"D Bradley","year":"2022","unstructured":"Bradley, D. et al. Interferon gamma mediates the reduction of adipose tissue regulatory T\u2009cells in human obesity. Nat. Commun. 13, 5606 (2022).","journal-title":"Nat. Commun."},{"key":"1554_CR19","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1161\/01.CIR.96.12.4219","volume":"96","author":"S-J Hwang","year":"1997","unstructured":"Hwang, S.-J. et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 96, 4219\u20134225 (1997).","journal-title":"Circulation"},{"key":"1554_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1172\/JCI11871","volume":"107","author":"MI Cybulsky","year":"2001","unstructured":"Cybulsky, M. I. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107, 1255\u20131262 (2001).","journal-title":"J. Clin. Invest."},{"key":"1554_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/0140-6736(93)90998-V","volume":"341","author":"PM Ridker","year":"1993","unstructured":"Ridker, P. M., Vaughan, D. E., Manson, J., Hennekens, C. & Stampfer, M. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341, 1165\u20131168 (1993).","journal-title":"Lancet"},{"key":"1554_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1161\/01.CIR.0000120705.55512.EC","volume":"109","author":"PE Morange","year":"2004","unstructured":"Morange, P. E. et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109, 1343\u20131348 (2004).","journal-title":"Circulation"},{"key":"1554_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13300-020-00962-3","volume":"12","author":"D Nikolic","year":"2021","unstructured":"Nikolic, D. et al. Liraglutide reduces carotid intima-media thickness by reducing small dense low-density lipoproteins in a real-world setting of patients with type 2 diabetes: a novel anti-atherogenic effect. Diabetes Ther. 12, 261\u2013274 (2021).","journal-title":"Diabetes Ther."},{"key":"1554_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1475-2840-13-49","volume":"13","author":"M Rizzo","year":"2014","unstructured":"Rizzo, M. et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc. Diabetol. 13, 49 (2014).","journal-title":"Cardiovasc. Diabetol."},{"key":"1554_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","volume":"15","author":"M Rizzo","year":"2016","unstructured":"Rizzo, M. et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc. Diabetol. 15, 162 (2016).","journal-title":"Cardiovasc. Diabetol."},{"key":"1554_CR26","doi-asserted-by":"publisher","first-page":"k3760","DOI":"10.1136\/bmj.k3760","volume":"362","author":"NM Astbury","year":"2018","unstructured":"Astbury, N. M. et al. Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial. Brit. Med. J. 362, k3760 (2018).","journal-title":"Brit. Med. J."},{"key":"1554_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean, M. E. J. et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 7, 344\u2013355 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1554_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(24)00194-3","volume":"12","author":"J Valabhji","year":"2024","unstructured":"Valabhji, J. et al. Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation. Lancet Diabetes Endocrinol. 12, 653\u2013663 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1554_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino, D. M. et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327, 138\u2013150 (2022).","journal-title":"JAMA"},{"key":"1554_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102475","volume":"69","author":"SBK Jensen","year":"2024","unstructured":"Jensen, S. B. K. et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 69, 102475 (2024).","journal-title":"EClinicalMedicine"},{"key":"1554_CR31","doi-asserted-by":"publisher","first-page":"e031431","DOI":"10.1136\/bmjopen-2019-031431","volume":"9","author":"SBK Jensen","year":"2019","unstructured":"Jensen, S. B. K. et al. Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. BMJ Open 9, e031431 (2019).","journal-title":"BMJ Open"},{"key":"1554_CR32","doi-asserted-by":"publisher","first-page":"F529","DOI":"10.1152\/ajprenal.00025.2019","volume":"317","author":"LA Mortensen","year":"2019","unstructured":"Mortensen, L. A. et al. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients. Am. J. Physiol. Renal Physiol. 317, F529\u2013F539 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1554_CR33","doi-asserted-by":"publisher","first-page":"e074992","DOI":"10.1136\/bmjopen-2023-074992","volume":"13","author":"VF Rasmussen","year":"2023","unstructured":"Rasmussen, V. F. et al. Cross-sectional study investigating the association between inflammatory biomarkers and neuropathy in adolescents with type 1 diabetes. BMJ Open 13, e074992 (2023).","journal-title":"BMJ Open"}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01554-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:51:28Z","timestamp":1784890288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01554-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1554"],"URL":"https:\/\/doi.org\/10.1038\/s42255-026-01554-4","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J.H. is on the advisory board of Novo Nordisk. L.M.O. currently works at Novo Nordisk and was employed after data collection and the end of the study. The spouse of T.B. works at Novo Nordisk; T.B. and spouse own Novo Nordisk stocks. In the last 5\u2009years, S.M. has been on the advisory boards of AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi and Bayer; received lecture fees from AstraZeneca and Novo Nordisk; been a research grant recipient from Novo Nordisk and Boehringer Ingelheim; and received support for attending meetings and\/or travel from Novo Nordisk and Boehringer Ingelheim. S.S.T. has received research grants and honoraria for lectures and has had a membership on an advisory panel for Novo Nordisk. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}